Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae

APMIS

Volumn 120, Issue 9, 2012, Pages 750-760

  Hadad, Ronza ^a   Jacobsson, Susanne ^a   Pizza, Mariagrazia ^b   Rappuoli, Rino ^b   Fredlund, Hans ^a   Olcén, Per ^a   Unemo, Magnus ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

4CMenB vaccine; Genome derived neisserial antigen (GNA); Neisseria gonorrhoeae

Indexed keywords

4 COMPONENT MENINGOCOCCUS SEROGROUP B VACCINE; BACTERIAL ANTIGEN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL HEPARIN BINDING ANTIGEN; PROTEIN NEISSERIA ADHESIN A; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; FACTOR H BINDING PROTEIN GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC POLYMORPHISM; MICROBIAL DIVERSITY; NEISSERIA ADHESIN A GENE; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NEISSERIAL HEPARIN BINDING ANTIGEN GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; STOP CODON;

AMINO ACID SEQUENCE; ANTIGENS, BACTERIAL; BASE SEQUENCE; DNA, BACTERIAL; GONORRHEA; HUMANS; MENINGOCOCCAL VACCINES; MOLECULAR SEQUENCE DATA; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS, SEROGROUP B; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

EID: 84865291540     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02903.x     Document Type: Article

References (44)

1. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
2. Perrin A, Bonacorsi S, Carbonnelle E, Talibi D, Dressen P, Nassif X, et al. Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect Immun 2002;70:7063-72.
3. Tinsley CR, Nassif X. Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities. Proc Natl Acad Sci USA 1996;93:11109-14.
4. Smith MJ. Meningococcal tetravalent conjugate vaccine. Expert Opin Biol Ther 2008;8:1941-6.
5. Center for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60:72-6.
6. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126:514-21.
7. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.
8. Guiliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9.
9. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5.
10. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50.
11. ™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6.
12. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003;188:1730-40.
13. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10.
14. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54.
15. Jacobsson S, Hedberg ST, Mölling P, Unemo M, Comanducci M, Rappuoli R, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009;27:1579-84.
16. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
17. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-9.
18. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99.
19. Welsch JA, Ram S. Factor H and neisserial pathogenesis. Vaccine 2008;26(Suppl 8):140-5.
20. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63:1142-51.
21. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000;287:1809-15.
22. Jacobsson S, Thulin S, Mölling P, Unemo M, Comanducci M, Rappuoli R, et al. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 2006;24:2161-8.
23. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004;189:1497-505.
24. Unemo M, Sjöstrand A, Akhras M, Gharizadeh B, Wretlind B, Fredlund H. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS 2007;115:231-41.
25. Unemo M, Olcén P, Berglund T, Albert J, Fredlund H. Molecular epidemiology of Neisseria gonorrhoeae: sequence analysis of the porB gene confirms presence of two circulating strains. J Clin Microbiol 2002;40:3741-9.
26. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-25.
27. Van de Peer Y, De Wachter R. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994;10:569-70.
28. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 2008;76:4232-40.
29. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008;76:2568-75.
30. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol 2009;46:1647-53.
31. Scarselli M, Cantini F, Santini L, Veggi D, Dragonetti S, Donati C, et al. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol 2009;386:97-108.
32. Giuliani MM, Santini L, Brunelli B, Biolchi A, Aricò B, Di Marcello F, et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 2005;73:1151-60.
33. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010;107:3770-5.
34. Turner DP, Wooldridge KG, Ala'Aldeen DA. Autotransported serine protease A of Neisseria meningitidis: an immunogenic, surface-exposed outer membrane, and secreted protein. Infect Immun 2002;70:4447-61.
35. Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 2011;29:1968-73.
36. Shaughnessy J, Lewis LA, Jarva H, Ram S. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun 2009;77:2094-103.
37. Rice PA, Vayo HE, Tam MR, Blake MS. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J Exp Med 1986;164:1735-48.
38. Wetzler LM, Barry K, Blake MS, Gotschlich EC. Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera. Infect Immun 1992;60:39-43.
39. Sparling P, Elkins C, Wyrick PB, Cohen MS. Vaccines for bacterial sexually transmitted infections: a realistic goal? Proc Natl Acad Sci USA 1994;91:2456-63.
40. Wetzler LM. The development of a gonococcal vaccine: fact or fiction? Int J STD AIDS 2001;12(Suppl. 2):12.
41. Zhu W, Chen CJ, Thomas CE, Anderson JE, Jerse AE, Sparling PF. Vaccines for gonorrhea: can we rise to the challenge. Front Microbiol 2011;2:124.
42. Borges O, Lebre F, Bento D, Borchard G, Junginger HE. Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res 2010;27:211-23.
43. Maiden MC, Stuart JM, Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-31.
44. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43.